Our Technology

NuPotential is leveraging its proprietary NP-Reprog cell reprogramming platform and NP-Epidrugs to develop in vitro models of disease, or "NP-Disease in a Dish," for preclinical drug discovery, toxicity testing, and disease research. Existing disease models have significant limitations in disease mimicry, survivability, and availability. NP-Disease in a Dish models will be a novel, cost-effective tool to recapture disease in vitro, providing needed improvements to current drug discovery and development platforms found within the pharmaceutical industry.

NP-Disease in a Dish models are prepared from minimally invasive tissue samples of patients that are suffering from various chronic disease indications. Using the novel and proprietary small molecule-focused NP-Reprog platform, tissue samples (skin, for instance) are reprogrammed to a pluripotent state and can then be differentiated into desired tissue lineages for numerous research and development applications. These cells, in addition to their development conduits (NP-iPS -pluripotent cell lines) will afford NuPotential and its prospective partners robust and flexible capabilities in; 1) disease R&D; 2) drug discovery and development; and 3) drug repositioning.

NP-Disease in a Dish highlights include:

Generated using the novel and proprietary NP-Reprog cell reprogramming platform: - Small molecule-based reprogramming platform with leading industrial scale-up potential. - Cell lines developed withNP-Reprog have advanced differentiation capacity . - Small molecule-based reprogramming does not alter genomic-related disease physiology.
Access to a large and diverse patient population to aid in the development of substantial libraries of disease models with patient-specific disease phenotypes of metabolic-related diseases.
PIER and NP-Reprog driven technology.
Strong IP support.

NP-Disease in a Dish models will first be generated from sufferers of metabolic disease-related indications (type 2 diabetes, obesity, heart disease). In vitro models of liver and neuronal associated chronic diseases are also in development. NuPotential will license NP-Disease ina Dish and complementary technologies for a potential partner's internal development, and, dependent on our partner's needs, will produce partner-specific NP-Disease in a Dish cell lines for thier use.